B. Riley lowered the firm’s price target on Perspective Therapeutics (CATX) to $9 from $17 and keeps a Buy rating on the shares. After taking another look at the dose-escalation data, B. Riley finds ...
Oppenheimer lowered the firm’s price target on Perspective Therapeutics (CATX) to $13 from $14 and keeps an Outperform rating on the shares following the company’s Q3 business update on Monday ...
UBS analyst David Lai lowered the firm’s price target on Perspective Therapeutics (CATX) to $7 from $18 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback